Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of NicoDerm CQ Patches (GSK Dungarvan vs Alza) in Smokers
NCT05024747Phase 1Completed
- Sponsor
- Haleon
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotine patch in Tobacco Use Disorder (TUD) (2 arms), sponsored by Haleon. Primary endpoints: Maximum Observed Plasma Nicotine Concentration, Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t and 1 more. Started Sep 2021; status: completed.
02
Drugs
nicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05024747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024747.